(3S)-3-[[(2S)-6-Amino-2-[[(2S)-2-Amino-5-(Diaminomethylideneamino)Pentanoyl]Amino]Hexanoyl]Amino]-4-[[(2S)-1-[[(2S)-1-[(4-Diphenylphosphorylphenyl)Methoxy]-3-(4-Hydroxyphenyl)-1-Oxopropan-2-Yl]Amino]-3-Methyl-1-Oxobutan-2-Yl]Amino]-4-Oxobutanoic Acid置于palladium On Activated Charcoal,氢气体系中,用 甲醇 作为反应溶剂,20.0 °C,482.64 Kpa 条件下,反应 24.0H,以87%的收率获得产物胸腺五肽 参考文献:通过设计 Gap 保护基团合成 Gap 肽:不含聚合物,色谱和重结晶的胸腺五肽 Fmoc/tbu 合成 标题:通过设计 Gap 保护基团合成 Gap 肽:不含聚合物,色谱和重结晶的胸腺五肽 Fmoc/tbu 合成 摘要:报道了一种新的 Fmoc/tbu 液相肽合成方法和一种新的苄基型 Gap 保护基团的开发.这种新的 Gap 保护基团用于代替聚合物载体,促进 C->n Fmoc 肽合成,无需色谱,重结晶或聚合物载体.gap基团可以高收率加入和去除,用于合成超过1克的免疫刺激剂胸腺五肽,总收率(83%)和纯度(99%). DOI:10.1002/ejoc.201600026
专利信息
专利号:US-12351573-B2 优先权日:2019-05-09 标 题:Compounds for use in synthesis of peptidomimetics 发明人:AL-ABED YOUSEF; CHENG KAI FAN 权利人:FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH 摘要:Synthesis of O-benzotriazole and O-imidazole synthons are described. Uses of synthons in synthesis of azapeptides and other peptidomimetics, azapeptides and other peptidomimetics synthesized from the synthons and uses of azapeptides and other peptidomimetics are also described.
专利号:US-2023159450-A1 优先权日:2020-05-08 标 题 :Dimers for use in synthesis of peptidomimetics 发明人:AL-ABED YOUSEF; ALTITI AHMAD 权利人:FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH 摘要:Dimers for use in synthesis of peptidomimetics are described. Uses of dimers as synthons in synthesis of azapeptides and other peptidomimetics, azapeptides and other peptidomimetics synthesized from the dimers and uses of azapeptides and other peptidomimetics are also described.
专利号:US-7122693-B2 优先权日:1988-04-11 标题 :Acetaldehyde acetal compounds, their synthesis, and uses thereof 发明人:BELLEAU EXECUTRIX OF ESTATE PI; DIXIT DILIP M; NGUYEN-BA NGHE 权利人:SHIRE BIOCHEM INC 摘要:The acetaldehyde compounds, 2-thiobenzoylacetaldehyde diethylacetal, 2-benzoyloxyacetaldehyde bis(2-methoxyethyl)acetal, 2-hydroxyacetaldehyde bis( 2-methoxyethyl)acetal, 2-thiobenzoylacetaldehyde bis(2-methoxy-ethyl)acetal, and 2-thioacetaldehyde bis(2-methoxyethyl)acetal, are useful as intermediates in the synthesis of substituted 1,3-oxathiolanes and substituted 1,3-dioxolanes.
专利号:US-5219988-A 优先权日:1989-02-22 标 题 :Gem-diamino derivatives and their use in the synthesis of retro-inverso peptides 发明人:GAZERRO LAURA; PINORI MASSIMO; VERDINI ANTONIO S 权利人:ENIRICERCHE SPA; SCLAVO SPA 摘要:This invention relates to new gem-diamino derivatives of general formula (I) ##STR1## where R is the side chain of an amino acid, of which any functional groups are suitably protected, and n X is an acyl group chosen from the group consisting of 2-nitrobenzoyl, 4-chloro-butyryl, acetoacetyl, 4-bromo-butyryl, (2-nitrophenoxy)-acetyl and 2-methyl-2-(2'-nitro-phenoxy)propionyl, of use in introducing gem-diamino residues into retro-inverso peptides. The invention further relates to a method for the synthesis of retro-inverso peptides in which the gem-diamino residue or residues are introduced using the new compound (I).
专利号:US-5962515-A 优先权日:1997-05-29 标题 :Process for isolation and synthesis of 1-(3,4 methylenedioxy-phenyl)-1E-tetradecene and its analogues and their activities against tumors and infections 发明人:UPADHYAY SHAKTI N; VISHWAKARMA RAM A; GHOSAL SABARI; SHUKLA SUPRIYA; BOSE CHANDA; KAMRA ANITA 权利人:NAT INST IMMUNOLOGY 摘要:Process for isolation of 1-(3,4-methylenedioxy-phenyl)-1E-tetradecene from Piper longum. Processes for synthesis of 1-(3,4-methylenedioxy-phenyl)-1E-tetradecene; its stereoisomers and analogues are disclosed. The compounds isolated and synthesized according to this invention have immunomodulatory properties and can be used to treat tumors and infections.
专利号:US-2010261876-A1 优先权日:2007-09-25 标 题:Novel methods of synthesis for therapeutic antiviral peptides 发明人:BRAY BRIAN L; JOHNSTON BARBARA E; SCHNEIDER STEPHEN E; TVERMOES NICOLAI A; ZHANG HUYI; FRIEDRICH PAUL E 权利人:BRAY BRIAN L; JOHNSTON BARBARA E; SCHNEIDER STEPHEN E; TVERMOES NICOLAI A; ZHANG HUYI; FRIEDRICH PAUL E 摘要:Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
1: Chen Y, Tian H, Zhang X, Nice EC, Huang C, Zhang H, Zheng S. Copper- coordination driven brain-targeting nanoassembly for efficient glioblastoma multiforme immunotherapy by cuproptosis-mediated tumor immune microenvironment reprogramming. J Nanobiotechnology. 2024 Dec 28;22(1):801. doi: 10.1186/s12951-024-03059-2. 2: Wang J, Tang Y, Zhao X, Ding Z, Ahmat M, Si D, Zhang R, Wei X. Molecular hybridization modification improves the stability and immunomodulatory activity of TP5 peptide. Front Immunol. 2024 Nov 11;15:1472839. doi: 10.3389/fimmu.2024.1472839. 3: Li Q, Wu A, Zhang M, Zhang X, Zang H. Adaptive covalently assembled thymopentin/hyaluronic acid based anti-inflammatory drug carrier with injectability and controlled release. Int J Biol Macromol. 2024 Dec;282(Pt 3):136923. doi: 10.1016/j.ijbiomac.2024.136923. Epub 2024 Oct 28. 277(Pt 1):133832. doi: 10.1016/j.ijbiomac.2024.133832. Epub 2024 Jul 11.
合成参考文献
参考文献:10.1126/science.abo7201 摘要:Boby ML, Fearon D, Ferla M, Filep M, Koekemoer L, Robinson MC; COVID Moonshot Consortium‡, Chodera JD, Lee AA, London N, von Delft A, von Delft F, Achdout H, Aimon A, Alonzi DS, Arbon R, Aschenbrenner JC, Balcomb BH, Bar-David E, Barr H, Ben-Shmuel A, Bennett J, Bilenko VA, Borden B, Boulet P, Bowman GR, Brewitz L, Brun J, Bvnbs S, Calmiano M, Carbery A, Carney DW, Cattermole E, Chang E, Chernyshenko E, Clyde A, Coffland JE, Cohen G, Cole JC, Contini A, Cox L, Croll TI, Cvitkovic M, De Jonghe S, Dias A, Donckers K, Dotson DL, Douangamath A, Duberstein S, Dudgeon T, Dunnett LE, Eastman P, Erez N, Eyermann CJ, Fairhead M, Fate G, Fedorov O, Fernandes RS, Ferrins L, Foster R, Foster H, Fraisse L, Gabizon R, García-Sastre A, Gawriljuk VO, Gehrtz P, Gileadi C, Giroud C, Glass WG, Glen RC, Glinert I, Godoy AS, Gorichko M, Gorrie-Stone T, Griffen EJ, Haneef A, Hassell Hart S, Heer J, Henry M, Hill M, Horrell S, Huang QYJ, Huliak VD, Hurley MFD, Israely T, Jajack A, Jansen J, Jnoff E, Jochmans D, John T, Kaminow B, Kang L, Kantsadi AL, Kenny PW, Kiappes JL, Kinakh SO, Kovar B, Krojer T, La VNT, Laghnimi-Hahn S, Lefker BA, Levy H, Lithgo RM, Logvinenko IG, Lukacik P, Macdonald HB, MacLean EM, Makower LL, Malla TR, Marples PG, Matviiuk T, McCorkindale W, McGovern BL, Melamed S, Melnykov KP, Michurin O, Miesen P, Mikolajek H, Milne BF, Minh D, Morris A, Morris GM, Morwitzer MJ, Moustakas D, Mowbray CE, Nakamura AM, Neto JB, Neyts J, Nguyen L, Noske GD, Oleinikovas V, Oliva G, Overheul GJ, Owen CD, Pai R, Pan J, Paran N, Payne AM, Perry B, Pingle M, Pinjari J, Politi B, Powell A, Pšenák V, Pulido I, Puni R, Rangel VL, Reddi RN, Rees P, Reid SP, Reid L, Resnick E, Ripka EG, Robinson RP, Rodriguez-Guerra J, Rosales R, Rufa DA, Saar K, Saikatendu KS, Salah E, Schaller D, Scheen J, Schiffer CA, Schofield CJ, Shafeev M, Shaikh A, Shaqra AM, Shi J, Shurrush K, Singh S, Sittner A, Sjö P, Skyner R, Smalley A, Smeets B, Smilova MD, Solmesky LJ, Spencer J, Strain-Damerell C, Swamy V, Tamir H, Taylor JC, Tennant RE, Thompson W, Thompson A, Tomásio S, Tomlinson CWE, Tsurupa IS, Tumber A, Vakonakis I, van Rij RP, Vangeel L, Varghese FS, Vaschetto M, Vitner EB, Voelz V, Volkamer A, Walsh MA, Ward W, Weatherall C, Weiss S, White KM, Wild CF, Witt KD, Wittmann M, Wright N, Yahalom-Ronen Y, Yilmaz NK, Zaidmann D, Zhang I, Zidane H, Zitzmann N, Zvornicanin SN. Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors. Science. 2023 Nov 10;382(6671):eabo7201.